PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO EVALUATE EDP-938 REGIMENS IN SUBJECTS AGED 28 DAYS TO 24 MONTHS INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS (RSV)
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Zelicapavir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms RSVPED
- Sponsors Enanta Pharmaceuticals
Most Recent Events
- 12 Mar 2025 According to an Enanta Pharmaceuticals media release, company will present data from this study at the 13th International RSV Symposium (RSV 2025) being held March 12-15 at Bourbon Cataratas do Iguazu, in Iguazu Falls, Brazil.
- 09 Dec 2024 According to an Enanta Pharmaceuticals media release, Jaime Deville is principal investigator in this trial. Full data from the study will be presented at a future medical conference or in a peer-reviewed publication.
- 09 Dec 2024 Results presented in an Enanta Pharmaceuticals media release.